OncoMatch/Clinical Trials/NCT07202364
A Study of YL202 in Patients With Advanced Solid Tumors
Is NCT07202364 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies YL202 for non small cell lung cancer.
Treatment: YL202 — This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Colorectal Cancer
Cervical Cancer
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: HER3-targeted therapy
Prior drug therapy targeting HER3
Cannot have received: topoisomerase I inhibitor
Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors
Cannot have received: allogeneic bone marrow transplantation
Prior treatment with allogeneic bone marrow transplantation
Cannot have received: solid organ transplantation
Prior treatment with ... solid organ transplantation
Lab requirements
Blood counts
The function of organs and bone marrow meets the requirements within 7 days prior to the first dose
Kidney function
The function of organs and bone marrow meets the requirements within 7 days prior to the first dose
Liver function
The function of organs and bone marrow meets the requirements within 7 days prior to the first dose
The function of organs and bone marrow meets the requirements within 7 days prior to the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify